SRSF2 and gastric cancer: Similarly, inhibition of Clk1 using TG003 and Clk1 siRNA resulted in a decreased cell viability, proliferation, invasion and migration as well as modulation in the phosphorylation of SRSF2, which validated the use of Clk1 as a potential target for gastric cancer treatment (Babu et al. 2020).